-
-
公开(公告)号：KR101207553B1
公开(公告)日：2012-12-03
申请号：KR1020050047235
申请日：2005-06-02
Applicant: (주)씨앤팜
CPC classification number: A61K9/0019 , A61K9/143 , A61K47/02
Abstract: 본발명은무독성금속이중층수산화물및 약제학적으로허용가능한첨가제를포함하는주사제용약물담체에관한것이다. 보다구체적으로, 본발명은다양한조성을갖는금속이중층수산화물을합성하는단계, 생체파괴를일으키지않는수준으로금속이중층수산화물의크기와입형을조절하는단계, 금속이중층수산화물을용매에분산시켜생체에주입하는단계를포함한다. 본발명에따르면, 생물체의혈관에영향을주지않는나노크기의금속이중층수산화물을합성할수 있으며, 이렇게합성된금속이중층수산화물은 400mg/kg 까지의투여량에도생체에악영향을끼치지않으면서, 특정약물의전달효율을높일수 있는약물전달체시스템을확립할수 있다.
-
公开(公告)号：KR1020120089991A
公开(公告)日：2012-08-16
申请号：KR1020110091796
申请日：2011-09-09
Applicant: (주)씨앤팜
IPC: C07D251/24 , C07D251/12 , C07D251/02 , A61K31/337
CPC classification number: A61K47/42 , A61K9/0019 , A61K9/107 , A61K9/4833 , A61K31/337 , A61K47/24 , C07F9/65815
Abstract: PURPOSE: A method for preparing an amphiphilic cyclic phosphazene trimer with biocompatibility is provided to improve physiochemical stability, efficacy, and toxicity of a drug. CONSTITUTION: Am amphiphilc cyclic phosphazene trimer is denoted by chemical formula 1[N=P(MPEG)(oligopeptide ester)]_3. The oligopeptide is C1-6 alkyl ester or C7-C13 aryl alkyl ester of hexapeptide to nanopeptide. The oligopeptide contains hydrophobic amino acids of glycine(Gly), phenyl alanine(phe), leucine(Leu), isoleucine alanine(Ala), alanine(Ala), or valine(Val). The hydrophobic drug is doxetacell or paclitaxel.
Abstract translation: 目的：提供一种制备具有生物相容性的两亲环磷腈三聚体的方法，以改善药物的生理化学稳定性，功效和毒性。 构成：Amphiphilc环磷腈三聚体由化学式1 [N = P（MPEG）（寡肽酯）] 3表示。 寡肽是六肽与纳米肽的C 1-6烷基酯或C 7 -C 13芳基烷基酯。 寡肽含有甘氨酸（Gly），苯丙氨酸（phe），亮氨酸（Leu），异亮氨酸丙氨酸（Ala），丙氨酸（Ala）或缬氨酸（Val）的疏水性氨基酸。 疏水性药物是多西他赛或紫杉醇。
-
34.发明授权불포화 지방산 및 층상형 금속 수산화물의 혼성체, 그 제조방법, 및 그 혼성체를 포함하는 기능성 식품 및 피부외용제 有权不饱和脂肪酸与层状金属氢氧化物的混合物，其制备方法和功能性食品以及包含其的皮肤外用制剂
公开(公告)号：KR100998354B1
公开(公告)日：2010-12-03
申请号：KR1020070122843
申请日：2007-11-29
Applicant: (주)씨앤팜
Abstract: 본 발명은 불포화 지방산의 층상형 금속 수산화물과의 혼성체에 관한 것으로, 보다 구체적으로는 불포화 지방산의 안정성을 증가시키면서 다양한 용매 및 제형에서 분산성이 뛰어나 제제화가 용이한 불포화 지방산의 층상형 금속 수산화물과의 혼성체, 그 제조방법, 및 그 혼성체를 포함하는 피부 외용제 및 기능성 식품에 관한 것이다.
불포화 지방산, 필수 지방산, 층상형 금속 수산화물, 혼성체-
公开(公告)号：KR1020090102996A
公开(公告)日：2009-10-01
申请号：KR1020080028305
申请日：2008-03-27
Applicant: (주)씨앤팜
Inventor： 강문식
IPC: A61K31/505 , A61P35/00
CPC classification number: A61K31/519 , A61K47/52 , A61K2121/00
Abstract: PURPOSE: An in vivo selective tumor suppressing method using layered dihydroxide is provided to selectively transfer anti-cancer drug to cancer tissue and prevent reduction of efficiency. CONSTITUTION: An in vivo selective tumor suppressing method using layered dihydroxide is performed by transferring to cancer cells and increasing residence time in the body compared with administering anti-cancer drug only. A composition of LDH and anti-cancer drug has targeting function of effectively treating cancer without any side effect. The cancer is osteosarcoma. The composite of the LDH and anti-cancer drug is manufactured in 50-450 nm by hydrothermal reaction.
Abstract translation: 目的：提供使用层状二氧化物的体内选择性肿瘤抑制方法，以选择性地将抗癌药物转移至癌组织，并防止效率降低。 构成：与仅施用抗癌药物相比，使用层状二氢氧化物的体内选择性肿瘤抑制方法通过转移到癌细胞并增加在体内的停留时间来进行。 LDH和抗癌药物的组合物具有有效治疗癌症的靶向功能，无任何副作用。 癌症是骨肉瘤。 LDH和抗癌药物的复合物通过水热反应在50-450nm制备。
-
Patent Agency Ranking
公开(公告)号：KR1020080009653A
公开(公告)日：2008-01-29
申请号：KR1020070073442
申请日：2007-07-23
Applicant: (주)씨앤팜
IPC: A61K9/18 , A61K9/14 , A61K31/164
CPC classification number: A61K9/1611 , A61K9/127 , A61K9/1629 , A61K9/1682 , A61K31/164
Abstract: A mixture material in which a complex of an active ingredient-micelle is hybridized into pores of a meso porous inorganic structure is provided to make a drug be stable at light and heat and show the controlled releasing property, thereby lowering the toxicity of the drug itself and also increasing the transmission efficiency of the drug into cells. A method for preparing the same is provided to simply obtain the mixture material with only two steps. A mixture material is characterized in that a complex of an active ingredient-micelle in which the active ingredient is supported on a micelle of a biocompatible copolymeric polymer surfactant is hybridized with pores of a meso porous inorganic structure, wherein the surfactant is a compound of EOnPOmEOn (n is an integer from 20-106 and m is an integer from 40-100), the meso porous inorganic structure is made of SiO2 or TiO2, and the active ingredient is a water-insoluble drug. A method for preparing the mixture material comprises the steps of: (a) reacting an aqueous solution of a mixture consisting of an active ingredient, a biocompatible copolymeric polymer surfactant with the concentration of more than the critical micelle formation, and an inorganic precursor at a temperature of 25-40 deg.C to form a complex of an active ingredient-micelle in which the active ingredient is supported on the micelle of the surfactant; and (b) subjecting the complex formed aqueous solution to hydrothermal reaction at a temperature of 80-130 deg.C to prepare an organic-inorganic complex.
Abstract translation: 提供其中将活性成分胶束的复合物与中孔多孔无机结构的孔杂交的混合材料，以使药物在光和热下稳定并显示出控制释放性质，从而降低药物本身的毒性 并且还将药物的传播效率提高到细胞中。 提供了制备该方法的方法以简单地仅获得两步的混合材料。 混合材料的特征在于将活性成分 - 胶束的复合物与活性成分负载在生物相容性共聚物表面活性剂的胶束上，与内消旋多孔无机结构的孔杂交，其中表面活性剂是EOnPOmOn的化合物 （n为20〜106的整数，m为40〜100的整数），中空多孔无机结构由SiO 2或TiO 2构成，活性成分为水不溶性药物。 一种制备该混合物材料的方法包括以下步骤：（a）使活性成分，生物相容性共聚物表面活性剂的浓度超过临界胶束形成的混合物的水溶液与无机前体反应， 温度为25-40℃，形成活性成分胶束的复合物，其中活性成分负载在表面活性剂的胶束上; 和（b）使复合物形成的水溶液在80-130℃的温度下进行水热反应以制备有机 - 无机络合物。
-
公开(公告)号：KR1020060125280A
公开(公告)日：2006-12-06
申请号：KR1020050047235
申请日：2005-06-02
Applicant: (주)씨앤팜
CPC classification number: A61K9/0019 , A61K9/143 , A61K47/02
Abstract: An injectable drug carrier comprising double-layered hydroxide is provided to remove a destruction risk of blood vessel by the double-layered hydroxide, and deliver an effective drug into the human body without toxicity and side effects. The injectable drug carrier comprises the nontoxic double-layered hydroxide and a pharmaceutically acceptable additive, wherein the particle size of the double layered hydroxide is 100-300 nm; and drug is MTX(methotrexate). The method for preparing the injectable drug carrier comprises the steps of: titrating divalent or trivalent metal salt solution with base solution to synthesize the double-layered hydroxide by hydro thermal method or at room temperature; and regulating the particle size of the synthesized double-layered hydroxide, wherein the divalent metal is magnesium, calcium or zinc, and the trivalent metal is aluminum or iron; and the base solution is sodium hydroxide or ammonia.
Abstract translation: 提供包含双层氢氧化物的可注射药物载体以通过双层氢氧化物去除血管的破坏风险，并将有效药物输送到人体内而没有毒副作用。 可注射药物载体包含无毒双层氢氧化物和药学上可接受的添加剂，其中双层氢氧化物的粒径为100-300nm; 药物是MTX（甲氨蝶呤）。 制备可注射药物载体的方法包括以下步骤：用碱溶液滴定二价或三价金属盐溶液，通过水热法或室温合成双层氢氧化物; 并调节合成的双层氢氧化物的粒度，其中二价金属是镁，钙或锌，三价金属是铝或铁; 碱溶液为氢氧化钠或氨。
-
38.发明公开
公开(公告)号：KR1020050020157A
公开(公告)日：2005-03-04
申请号：KR1020030057890
申请日：2003-08-21
Applicant: (주)씨앤팜
IPC: A61K47/48
CPC classification number: A61K9/1635 , A61K9/143 , A61K47/50
Abstract: PURPOSE: A hybrid of amlodipine with layered silicate and a preparation process thereof are provided, which hybrid is easily dispersed in aqueous solution to increase bioavailability of amlodipine, and is non-hygroscopic enabling easy manufacturing of formulation. CONSTITUTION: The hybrid of amlodipine with layered silicate is provided, wherein the amlodipine is inserted between layers of silicate; the layered silicate is selected from montmorillonite, beidellite, nontronite, hectorite, saponite, illite, celadonite, gluconite, clay and bentonite; inorganic salt or organic base is added into the hybride in order to regulate release of amlodipine; the organic base is aminoalkyl metacrylate copolymer or polyvinylacetal diethylaminoacetate; and the inorganic salt is selected from calcium salt, sodium salt, potassium salt and ammonium salt. The process for preparing the hybrid of amlodipine with layered silicate comprises the steps of: (1) dispersing the layered silicate in aqueous solution; (2) dissolving amlodipine in ethanol or water; and (3) mixing the layered silicate solution with the amlodipine solution and stirring them.
Abstract translation: 目的：提供氨氯地平与层状硅酸盐的混合物及其制备方法，其混合物容易分散在水溶液中以提高氨氯地平的生物利用度，并且是非吸湿性的，使制剂容易制造。 构成：提供氨氯地平与层状硅酸盐的混合物，其中氨氯地平插入硅酸盐层之间; 层状硅酸盐选自蒙脱石，贝得石，脱镁石，锂蒙脱石，皂石，伊利石，青瓷，葡萄糖甙，粘土和膨润土; 将无机盐或有机碱加入到混合物中以调节氨氯地平的释放; 有机碱是氨基烷基甲基丙烯酸酯共聚物或聚乙烯醇缩二乙基氨基乙酸酯; 无机盐选自钙盐，钠盐，钾盐和铵盐。 制备氨氯地平与层状硅酸盐的混合物的方法包括以下步骤：（1）将层状硅酸盐分散在水溶液中; （2）将氨氯地平溶于乙醇或水中; 和（3）将层状硅酸盐溶液与氨氯地平溶液混合并搅拌。
-
公开(公告)号：KR100443892B1
公开(公告)日：2004-08-09
申请号：KR1020010046774
申请日：2001-08-02
Applicant: (주)씨앤팜
IPC: C07F19/00
Abstract: PURPOSE: Provided are vitamin-inorganic hybrid which has excellent stability to heat, light and oxygen and excellent dispersibility, and sustainedly releases vitamin to maintain efficacies of vitamin for a ling time, and a preparation thereof. CONSTITUTION: The vitamin-inorganic hybrid complex is characterized by inserting vitamin or its derivative between layers of layered double metal hydroxide as an inorganic carrier by ion exchange reaction. It is represented by the formula:(M¬2+ 1-x N¬3+ x (OH)2)(A¬n-)x/n yH2O.
Abstract translation: 用途：提供一种维生素 - 无机杂化剂，其对热，光和氧具有优异的稳定性和优异的分散性，并持续释放维生素以维持维生素的疗效，并提供一种制剂。 组成：维生素 - 无机杂化复合物的特征在于通过离子交换反应将维生素或其衍生物插入层状双金属氢氧化物层之间作为无机载体。 它由下式表示：（M 2+ 2+ 1-x N 3+ x（OH）2）（A n - n - ）x / n y H 2 O.
-
公开(公告)号：KR1020030014182A
公开(公告)日：2003-02-15
申请号：KR1020020047318
申请日：2002-08-10
Applicant: (주)씨앤팜
Abstract: PURPOSE: A process of preparing a hybrid material containing 3-benzoyl-α -methylbenzene acetic acid, 4-biphenyl acetic acid, minocycline, etc. is provided. Whereby, the new hybrid material is useful in stabilization and delivery of specified drugs, low in adverse effects and excellent in stability and can be used in the form of an ointment, patch, oral administration, injection or the like. CONSTITUTION: The hybrid material is prepared by coprecipitation or ion exchange reaction of: a drug selected from the group consisting of 3-benzoyl-α-methylbenzene acetic acid, 4-biphenyl acetic acid and minocycline; and a layered inorganic material selected from the group consisting of layered silicate, layered aluminosilicate, layered phosphate and layered metal oxide.
Abstract translation: 目的：提供一种制备含3-苯甲酰基-α-甲基苯乙酸，4-联苯乙酸，米诺环素等的杂化材料的方法。 因此，新的混合材料可用于稳定和递送特定药物，不良反应低，稳定性优异，可以以软膏，贴剂，口服给药，注射等形式使用。 构成：杂化材料通过共沉淀或离子交换反应制备：选自3-苯甲酰基-α-甲基苯乙酸，4-联苯乙酸和米诺环素的药物; 以及选自层状硅酸盐，层状硅铝酸盐，层状磷酸盐和层状金属氧化物的层状无机材料。
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.028 seconds)
